<DOC>
	<DOCNO>NCT02761642</DOCNO>
	<brief_summary>This study evaluate efficacy safety subcutaneous ( SC ) r-HuEPO anemic participant breast cancer undergo chemotherapy .</brief_summary>
	<brief_title>A Study Recombinant Human Erythropoietin Beta ( r-HuEPO ) ( NeoRecormon ) Anemic Participants With Breast Cancer Undergoing Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult female participant histological diagnosis breast cancer Any type chemotherapy plan great equal ( &gt; /= ) 9 week Hemoglobin le ( &lt; ) 11 gram per deciliter ( g/dL ) Participants able receive iron supplement , necessary Known suspect contraindication rHuEPO Pregnancy lactation period Diagnosis anemia due irondeficiency Diagnosis thalassemic syndrome Epilepsy and/or cerebral metastasis Blood transfusion treatment erythropoietic agent within 4 week study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>